Document is current

Article History

Received: 13 March 2024

Accepted: 1 July 2024

First Online: 6 November 2024

Acknowledgements

: The SWEET e.V. Registry is funded by the SWEET members, including the SWEET corporate members, namely Abbott, Boehringer Ingelheim, Dexcom, Insulet, Eli Lilly, Medtronic Europe, Novo Nordisk and Sanofi. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the corporate members. The authors thank the following individuals for their support of this work: S. Tittel and S. Lanzinger for data management, and A. Hungele and R. Ranz for the SWEET-DPV software (all from Ulm University, Germany); M. Witsch (Centre Hospitalier de Luxembourg, Luxembourg), T. Danne and O. Kordonouri (Kinder- und Jugendkrankenhaus Auf Der Bult, Hannover, Germany) for centre integration; K. Klee and N. Koller (Kinder- und Jugendkrankenhaus Auf Der Bult) for initiating the SWEET collaboration; and S. Lanzinger and R. Holl (both Ulm University) for invaluable support. Finally, the authors thank all centres of the SWEET network, especially the collaboration centres that participated in this investigation.Parts of this study were presented in the oral presentation session at the 83rd Scientific Session of the American Diabetes Association (San Diego, 23–26 June 2023), and in the poster presentation session at the 57th European Diabetes Epidemiology Group annual meeting (Soesterberg, the Netherlands, 22–25 April 2023).

: Access to the programming code may be provided by the corresponding author if requested. For reasons of data protection, data at the individual level cannot be provided.

: Open Access funding enabled and organized by Projekt DEAL. The SWEET Registry is a non-profit charity registered in Hannover, Germany. It is financed through membership fees from the participating centres (based on the income of the country of residence, according to the World Bank) and corporate members. We acknowledge with gratitude the support from the following SWEET corporate members (in alphabetical order): Abbott, Boehringer Ingelheim, Dexcom, Insulet, Eli Lilly, Medtronic Europe, Novo Nordisk and Sanofi. The SWEET project is an ongoing registered research collaboration (ClinicalTrials.gov registration number NCT04427189).

: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: RG and VC designed the study, participated in data interpretation and wrote the manuscript. AJE performed the statistical analysis, participated in data interpretation, and reviewed and edited the manuscript. SB, NAC, FC, JK, CJ, EFG, AV, SS and SA researched data and reviewed and edited the manuscript. All authors approved the final version of the manuscript. RG, VC and AJE are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.